http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes
-
ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®
-
ProtoKinetix AAGP® Restores Vision in Blind Test Subjects
-
Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada
-
ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing
-
Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada
-
ProtoKinetix AAGP® Dry Eye Program Advancing
-
ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease
-
ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials
-
ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease
-
ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine
-
ProtoKinetix Files for Patent Protection for the Use of AAGP® in Transplant Medicine
-
ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial
-
ProtoKinetix AAGP® Dry Eye Therapy Testing Results
-
ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed
-
ProtoKinetix AAGP® Dry Eye Therapy Program Launched
-
ProtoKinetix AAGP® Operational Update
-
Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone
-
ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC

